This was a randomised, double-blind study, placebo-controlled study in over 10,000 participants, and was designed to investigate if canakinumab could prevent recurrent vascular events in patients with a persistent pro-inflammatory response (defined by elevated C-reactive protein levels (CRP)) following myocardial infarction. Here, CRP is linked to myocardial infarction.